Evaxion Biotech Total Long Term Liabilities 2020-2024 | EVAX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evaxion Biotech total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Evaxion Biotech total long term liabilities from 2020 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$178.8B
Regeneron Pharmaceuticals (REGN)	$126.4B
Vertex Pharmaceuticals (VRTX)	$124.2B
Gilead Sciences (GILD)	$103.4B
Bristol Myers Squibb (BMY)	$100.3B
CSL (CSLLY)	$97.4B
GSK (GSK)	$88.2B
Alnylam Pharmaceuticals (ALNY)	$35.2B
Argenex SE (ARGX)	$31.2B
BioNTech SE (BNTX)	$29.7B
Biogen (BIIB)	$28.9B
Moderna (MRNA)	$27.7B
Illumina (ILMN)	$20.7B
BeiGene (BGNE)	$19.2B
Genmab (GMAB)	$17.5B
BioMarin Pharmaceutical (BMRN)	$13.4B
Vaxcyte (PCVX)	$13B
Incyte (INCY)	$12.8B
Insmed (INSM)	$12.6B
Exact Sciences (EXAS)	$12.6B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.9B
QIAGEN (QGEN)	$10.4B
Legend Biotech (LEGN)	$9.3B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.9B
Ascendis Pharma (ASND)	$8.5B
Intra-Cellular Therapies (ITCI)	$7.9B
Exelixis (EXEL)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B